Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
Insmed reported strong first-quarter 2026 growth, with total revenues of $306.0 million, up from $92.8 million a year earlier, driven by the U.S. launch of BRINSUPRI and continued ARIKAYCE demand. BRINSUPRI generated $207.9 million, while ARIKAYCE contributed $98.1 million and remained in growth eight years post-launch.
The company still posted a net loss of $163.6 million, though this narrowed from $256.6 million in 2025 as operating leverage improved. Management reiterated 2026 revenue guidance of at least $1 billion for BRINSUPRI and $450–$470 million for ARIKAYCE, and highlighted a goal of reaching cash-flow positivity in 2027 supported by roughly $1.2 billion in cash and marketable securities.
Insmed reported sharply higher revenue but remained unprofitable in the quarter ended March 31, 2026. Product revenues, net rose to $305.964 million from $92.823 million a year earlier, driven by the US launch of BRINSUPRI, which contributed $207.854 million, while ARIKAYCE generated $98.110 million.
Net loss narrowed to $163.563 million from $256.583 million, reflecting higher sales but continued heavy investment in research, development, and commercialization. Operating expenses reached $459.284 million, including $209.485 million for research and development and $247.259 million for selling, general and administrative activities.
Insmed ended the quarter with $582.188 million in cash and cash equivalents and $641.326 million in marketable securities, supporting ongoing losses and pipeline spending. Total assets were $2.076 billion against total liabilities of $1.371 billion, including $542.215 million of long-term debt and $162.137 million related to a royalty financing agreement.
Insmed Inc Chair and CEO William Lewis reported a series of routine equity transactions in the company’s common stock. On May 4, 2026, he sold 10,699 shares in multiple open-market trades at weighted average prices ranging from about $134 to $139.60 per share, executed under a Rule 10b5-1 trading plan adopted on September 4, 2025.
On the same date, he exercised stock options to acquire a total of 10,699 shares of common stock at exercise prices of $17.16 and $30.46 per share. The filing also reflects an indirect holding of 233,924 shares held by trust, indicating Lewis continues to maintain a significant ownership position in Insmed alongside these transactions.
FMR LLC reports beneficial ownership of 13,145,166.52 shares of INSMED INC common stock, representing 6.1% of the class as of 03/31/2026. The filing (Schedule 13G) lists sole dispositive power for 13,145,166.52 shares and zero shared voting/dispositive power. The CUSIP is 457669307 and the filing identifies Abigail P. Johnson in a related capacity.
INSM submitted a Form 144 reporting proposed sales of Common stock. The filing, dated 05/04/2026, lists multiple sale entries by William Lewis with transaction dates from 02/03/2026 through 04/16/2026. The entries are recorded under "Stock Plan Activity" and identify Common shares to be sold on NASDAQ.
Insmed Inc reported a Schedule 13G filing showing Vanguard Capital Management beneficially owned 11,514,893 shares of Common Stock, representing 5.34% of the class as of 03/31/2026. The filer reports 1,872,762 shares of sole voting power and sole dispositive power over 11,514,893 shares.
INSMED Inc Chair and CEO William Lewis exercised stock options and sold shares in INSMED Inc. On April 16, 2026, he exercised options for 10,699 shares of Common Stock at exercise prices of $30.46 and $17.16 per share.
That same day he sold a total of 10,699 shares of Common Stock in open-market transactions at weighted average prices between $142.39 and $146.02 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions he directly held 301,185 shares, with an additional 233,924 shares held indirectly by a trust.
INSM reports proposed sales of Common stock on a Form 144, listing multiple sale dates and share counts attributable to William Lewis under stock plan activity. The filing lists transactions dated 04/06/2026, 03/19/2026, 03/05/2026, and earlier 2026 dates with corresponding numeric entries.
Insmed Inc Chair and CEO William Lewis reported option exercises and share sales in Insmed common stock. On April 6, 2026, he exercised stock options for a total of 10,699 shares at strike prices of $30.46 and $17.16 per share, then sold 10,699 shares in open-market transactions at weighted average prices around $161.73, $163.23, and $164.01. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly owned about 301,185 shares of common stock, with an additional 233,924 shares held indirectly through the Katie Procter Dynasty Trust.
Insmed Incorporated reported that its Phase 2b CEDAR trial of brensocatib in moderate to severe hidradenitis suppurativa did not meet its primary or secondary efficacy endpoints, and the company will discontinue development of brensocatib for HS.
The randomized, double-blind, placebo-controlled study enrolled 214 patients across 72 global sites. At Week 16, abscess and inflammatory nodule counts fell 45.5% and 40.3% in the 10 mg and 40 mg brensocatib arms, compared with a 57.1% reduction on placebo, indicating no efficacy advantage. Safety was consistent with prior studies, with similar rates of treatment-emergent adverse events and no new safety signals at either dose.